Letters
Appraisal of drugs for type 2 diabetes
Basing approval of drugs for type 2 diabetes on real world outcomes
BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5829 (Published 03 November 2015) Cite this as: BMJ 2015;351:h5829
- Andrew McGovern, clinical researcher1,
- Robert Hinchliffe, senior lecturer in vascular surgery2,
- Neil Munro, visiting professor1,
- Simon de Lusignan, professor of primary care1
- 1Section of Clinical Medicine and Ageing, University of Sussex, Guildford GU2 7PX, UK
- 2St George’s Vascular Institute, Division of Cardiovascular Sciences, St George’s, University of London, London, UK
- andy{at}mcgov.co.uk
Naci and colleagues rightly point out that although drugs are often approved on the basis of glucose lowering efficacy, we really need agents that reduce important outcomes such as symptomatic microvascular disease and cardiovascular events.1 The authors suggest that real world evidence of clinical effectiveness should be required from the drug industry, using routine healthcare data to monitor …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.